DK2311869T3 - Anvendelse af pattedyrcytokinrelaterede reagenser - Google Patents

Anvendelse af pattedyrcytokinrelaterede reagenser

Info

Publication number
DK2311869T3
DK2311869T3 DK10011810.8T DK10011810T DK2311869T3 DK 2311869 T3 DK2311869 T3 DK 2311869T3 DK 10011810 T DK10011810 T DK 10011810T DK 2311869 T3 DK2311869 T3 DK 2311869T3
Authority
DK
Denmark
Prior art keywords
related reagents
mammalian cytokine
cytokine
mammalian
reagents
Prior art date
Application number
DK10011810.8T
Other languages
Danish (da)
English (en)
Inventor
Waal Malefyt Rene De
Yong-Yun Liu
Wei Yuan
Vassili Soumelis
Marehalli L Nagalakshmi
Norihiko Watanabe
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27734298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2311869(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK2311869T3 publication Critical patent/DK2311869T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK10011810.8T 2002-02-01 2003-01-30 Anvendelse af pattedyrcytokinrelaterede reagenser DK2311869T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35350902P 2002-02-01 2002-02-01
EP09005325A EP2077277A1 (en) 2002-02-01 2003-01-30 Use of mammalian cytokine; related reagents

Publications (1)

Publication Number Publication Date
DK2311869T3 true DK2311869T3 (da) 2013-03-18

Family

ID=27734298

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10011810.8T DK2311869T3 (da) 2002-02-01 2003-01-30 Anvendelse af pattedyrcytokinrelaterede reagenser

Country Status (11)

Country Link
US (5) US20030186875A1 (https=)
EP (3) EP2077277A1 (https=)
JP (4) JP2005516606A (https=)
AU (1) AU2003208888B2 (https=)
CA (1) CA2474011C (https=)
DK (1) DK2311869T3 (https=)
ES (1) ES2399503T5 (https=)
MX (1) MXPA04007426A (https=)
NZ (1) NZ533987A (https=)
PT (1) PT2311869E (https=)
WO (1) WO2003065985A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
IL143034A0 (en) 1998-11-13 2002-04-21 Immunex Corp Human tslp dna and polypeptides
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
US7288633B2 (en) 2001-07-23 2007-10-30 Immunex Corporation Modified human thymic stromal lymphopoietin
DK2311869T3 (da) * 2002-02-01 2013-03-18 Merck Sharp & Dohme Anvendelse af pattedyrcytokinrelaterede reagenser
PL1651247T3 (pl) * 2003-07-18 2009-04-30 Schering Corp Leczeni i diagnozowanie nowotworów przy użyciu limfopoetyny zrębu grasicy
ATE556134T1 (de) * 2004-03-22 2012-05-15 Osiris Therapeutics Inc Mesenchymstammzellen und verwendungendafür
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CA2671538A1 (en) 2006-12-14 2008-06-26 Leonard G. Presta Engineered anti-tslp antibody
JP2010530233A (ja) * 2007-06-20 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー アレルギー疾患を処置する方法および組成物
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US12331304B2 (en) 2008-02-01 2025-06-17 Ceres, Inc. Promoter, promoter control elements, and combinations, and uses thereof
US20120124701A1 (en) 2008-02-01 2012-05-17 Ceres, Inc. Promoter, promoter control elements, and combinations, and use thereof
EP2213682A1 (en) * 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
PH12012500843A1 (en) * 2009-11-04 2019-07-10 Merck Sharp & Dohme Engineered anti-tslp antibody
WO2012001889A1 (ja) * 2010-06-28 2012-01-05 国立大学法人東北大学 Tslpを恒常的に高発現する細胞、及び前記細胞を利用したtslp調節剤のスクリーニング方法
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
JP2012032655A (ja) * 2010-07-30 2012-02-16 Fujimori Sangyo Kk ホログラム付きラミネートフィルム及びその製造方法、これを用いた容器
CA2853247A1 (en) * 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Il-19 as a biomarker of tslp treatment
EP2773774A4 (en) 2011-11-03 2015-06-10 Merck Sharp & Dohme BIOMARKERS FOR TSLP TREATMENT
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
JP6516925B2 (ja) 2015-09-09 2019-05-22 ノバルティス アーゲー 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6982320B2 (en) * 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
WO2000017362A1 (en) * 1998-09-21 2000-03-30 Schering Corporation Human interleukin-b50, therapeutic uses
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
IL143034A0 (en) * 1998-11-13 2002-04-21 Immunex Corp Human tslp dna and polypeptides
JP4469551B2 (ja) * 2000-06-16 2010-05-26 仁 水谷 カスパーゼ１遺伝子導入動物
DK2336187T3 (en) * 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
AU2001271624A1 (en) * 2000-06-28 2002-01-08 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
DK2311869T3 (da) * 2002-02-01 2013-03-18 Merck Sharp & Dohme Anvendelse af pattedyrcytokinrelaterede reagenser

Also Published As

Publication number Publication date
EP2311869B1 (en) 2012-12-19
EP2311869A1 (en) 2011-04-20
ES2399503T5 (es) 2021-04-08
CA2474011C (en) 2014-03-25
JP2012184259A (ja) 2012-09-27
US20100136003A1 (en) 2010-06-03
AU2003208888B2 (en) 2006-10-19
ES2399503T3 (es) 2013-04-01
JP2009132730A (ja) 2009-06-18
EP1487865A2 (en) 2004-12-22
NZ533987A (en) 2007-04-27
MXPA04007426A (es) 2004-10-11
WO2003065985A3 (en) 2004-10-14
CA2474011A1 (en) 2003-08-14
WO2003065985A2 (en) 2003-08-14
US20030186875A1 (en) 2003-10-02
JP2014156478A (ja) 2014-08-28
US20090017018A1 (en) 2009-01-15
EP2311869B2 (en) 2020-06-17
US20070020262A1 (en) 2007-01-25
US20110229434A1 (en) 2011-09-22
AU2003208888A1 (en) 2003-09-02
EP2077277A1 (en) 2009-07-08
EP1487865A4 (en) 2005-12-14
JP5519946B2 (ja) 2014-06-11
PT2311869E (pt) 2013-03-04
JP2005516606A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
DK2311869T3 (da) Anvendelse af pattedyrcytokinrelaterede reagenser
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
DK1470732T3 (da) Fremskaffelse af lokaliseringsinformation
DK1487805T3 (da) Pyrimidinderivater
DK1532474T3 (da) Markering af rørforforbindelser
EP1546115A4 (en) Substituted pyrimidines
DK1360169T3 (da) Succinatsalt af O-desmethyl-venlafaxin
EP1771786A4 (en) SAMPLE PROCESSING SIMULTANEOUS
ITMI20041123A1 (it) Fissaggio
DK2206517T3 (da) Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
DE60300734D1 (de) Anordnungen zur Vorbehandlung von Proben
DK1476162T3 (da) Kontrolleret syntese af ziprasidone
DE602004009744D1 (de) Reagenzbehälter
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1663991T3 (da) Selektiv syntese af CF3-substituerede pyrimidiner
DK1563061T3 (da) Dyrkning af hårinducerende celler
DK1625153T3 (da) Acylerede nonadepsipeptider af typen Lysobactin
NO20044145L (no) Assay for anti-INGAP antistoffer
DK1472412T3 (da) Byggesæt af brosten
FI20022003L (fi) Monikanavapipetti
SI2311869T1 (sl) Uporaba sesaläśevih s citokini povezanih reagentov
DK1675601T4 (da) Moderering af virkningen af enterotoksiner
UA6645S (uk) Центрифуга лабораторна
DE60329150D1 (de) Selbstnivellierender Hydrometer
UA9239S (uk) Комплект етикеток